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Abstract 
Chronic myelomonocytic leukemia is a very rare blood cancer observed mostly in the 
elderly. Here we report the incidence trends and survival of patients with chronic 
myelomonocytic leukemia over a 15-year period (1993-2007). Cases were provided by the 
population-based Girona Cancer Registry. The crude incidence rate was 0.72/100,000 
inhabitants/year. No statistically significant increase in trends was detected over the 15 
years. Median overall survival was 28 months although survival markedly decreased with 
advancing age. The 5-years observed and relative survival were 20% and 29%, 
respectively. This is the first population-based study that reports the incidence and survival 
of chronic myelomonocytic leukemia in Spain.  
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survival, population-based cancer registry 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
Chronic myelomonocytic leukemia (CMML) is a very rare haematopoietic disease 
characterized by myeloproliferative and myelodysplastic features. The classification of 
CMML within myeloid neoplasms was controversial for many years until its categorization 
by the World Health Organization (WHO) in 2001 [1]. The new classification considered 
this disease to fall within an independent group of myeloid neoplasms which share both 
qualities: proliferation and dysplasia [2-6]. This group of 
myelodysplastic/myeloproliferative neoplasms comprises, apart from CMML, juvenile 
myelomonocytic leukemia (JMML), atypical chronic myeloid leukemia (aCML, BCR-
ABL1 negative) and myelodysplastic/myeloproliferative diseases, unclassifiable [5-7].  
It is known that the median age of CMML diagnosis ranges from 65 to 75 years with a 
male predominance of 1.5-3.1:1 [2,4,6]. When this disease occurs in children it is called 
JMML. It usually appears in children under 6 years of age and a similar male predominance 
is detected, as with CMML [2,4,6]. 
While information on risk factors is not well defined, it is known that male gender, 
advanced age, previous exposure to adverse environment substances like carcinogens or 
ionizing radiation and chemotherapy treatment for a previous cancer may increase the risk 
of suffering CMML [6,8]. Prognostic factors, on the other hand, have been well described. 
Some studies have shown that anaemia, presence of circulating immature myeloid cells and 
percentage of blast in bone marrow can influence the prognosis of CMML, as well as 
cytogenetic alterations (which occur in 20-40% of cases) and somatic mutations in some 
genes like TET2, CBL, JAK2, KRAS, RAS, RUNX1 and ASXL1 [2,5,6,9-14]. 
Although median survival for CMML patients is around 12-24 months, it can vary from 1 
to over 100 months due to disease heterogeneity [2,5-7,11].   
There are no reliable CMML incidence data because in some epidemiological surveys it is 
grouped with chronic myeloid leukemia (CML) and in others regarded as myelodysplastic 
syndrome (MDS). Given that few population based data are reported [15,16], it is important 
to have more data regarding incidence and survival of this disease to provide clinicians with 
more useful and reliable information. 
 
The aims of this study were: a) to estimate the CMML incidence trends in the province of 
Girona during the period 1993-2007, and b) to estimate survival according to sex, age and 
year of diagnosis.   
PATIENTS AND METHODS 
Data 
Data were extracted from the population-based Girona Cancer Registry (GCR). The GCR is 
located in the Northeast of Catalonia, Spain, covering a population of 706,185 inhabitants 
as of the 2007 census [17]. Information sources for the cancer registry are regional and 
taken from community hospitals, haematology and pathology departments, and death 
certificates. The completeness of the registry is 96.3%. 
Population data used for the statistical analyses were provided by the Institut d’Estadística 
de Catalunya (Catalonia Statistics Institute or IDESCAT) [17]. We restricted our statistical 
analysis to the population diagnosed with CMML resident in Girona province from 1993 to 
2007. The second edition of Diseases for Oncology (ICD-O-2) [18] was used by the GCR 
up until 1997 and the third edition of International Classification of Diseases for Oncology 
(ICD-O-3) [19] has been used since 1998. The ICD-O-2 code for cases diagnosed with 
CMML before 1998 (code: 9868/3) was converted into ICD-O-3 code (code: 9945/3) after 
consulting the pathological and haematological results of the initial diagnosis. The GCR 
used ICD-O-3 classification codes to register haematological malignancies diagnosed 
between 1998 and 2001 according to proposals included in the WHO classification [20]. 
 
Incidence 
The mean and the standard deviation (SD) were calculated overall and by sex and 
compared using a t test. Incidence was calculated as the crude rate (CR), the age-
standardized rate for the world standard population (ASRW) and the age-specific rate for 5-
years overall and by sex [2,6]. Epidat software was used to compute CR and ASR with a 
95% confidence interval (95% CI), using the direct method [21]. The results were 
expressed in cases per 100,000 inhabitants/year. 
In order to compare our results with other international studies related to incidence of 
CMML, we also calculated the age-standardized rate (ASR) using the European and 
American populations as standards.  
Time trends related to incidence rates by CMML were assessed through the estimated 
annual percentage change (EAPC) of the incidence standardized rates. The Joinpoint log-
linear regression model was used to calculate EAPC with their 95% CI [22]. The standard 
parametric Fisher test was used to corroborate whether differences in incidence rates 
between years were statistically significant. 
 
Survival 
Follow-up time was calculated as the difference between the date of diagnosis and date of 
death, if the patient was dead, or the end of the follow-up study (December 31st, 2010) if 
the patient was alive when the period study ended. Vital status of patients was obtained by 
linking records to the Catalan Registry of Mortality and the National Death Index [23,24].  
In order to evaluate and compare survival time, we calculated observed survival (OS) 
overall, by sex, by age (<75 years and ≥75 years) and by year of diagnosis (1993-1997, 
1998-2002 and 2003-2007) [2,4,6]. OS curves were calculated using the nonparametric 
Fleming-Harrington method because risk was not proportional, and G-rho tests were used 
to compare the curves between sex and age [25,26]. Analyses were performed using R 
software. Statistical significance was determined at p=0.05.  
Due to the advanced age of patients and competing causes of mortality other than CMML, 
relative survival (RS) was estimated with 95% CI. It was computed using WAERS [27], a 
web-based application developed by the Catalan Institute of Oncology [28] which uses the 
Hakulinen method to estimate expected survival [29].  
RESULTS 
During the period 1993-2007, a total of 61 cases of CMML were reported by the GCR. 
This represented 1.45% (61/4202) of all haematological malignancies diagnosed in Girona 
province during the same period and 6.53% (61/934) of all myeloid neoplasms.  
 
Incidence 
Table 1 shows descriptive results and incidence. Of these patients, 25 were women 
(40.98%), with a mean age (SD) of 78.64 years (9.13), and 36 were men (59.02%), with a 
mean age (SD) of 79.03 years (7.31). Differences in age between sex were not statistically 
significant (p=0.86). A male predominance was found for CMML, with a sex ratio of 1.79, 
although this was not statistically significant (p= 0.88).  
CR was higher in men than in women (0.85 and 0.59 respectively). Corresponding overall 
ASRW expressed in 100,000 inhabitants/year was 0.25 for the two sexes (0.34 in men and 
0.19 in women). Monitoring incidence time trends by Joinpoint regression there was no 
evidence of change. EAPC was 3.29% with a 95% CI of -2.09 to 8.96 (data not shown). 
The standard parametric Fisher test showed a p=0.13, therefore the increase of the rate can 
be approximated parametrically in a straight line.  
As Figure 1 shows, CMML age-specific rate increases with age in both sexes. Under 74 the 
incidence was similar by sex but for the older age groups the incidence was higher among 
males than females. 
 
 
Survival 
Five-year OS and RS of patients diagnosed with CMML were 20% and 29%, respectively 
(Figure 2). In this cohort, the median OS was 28 months (95% CI: 15.90;40.01) (Figure 
3A).  
No statistically significant difference in survival curves was observed between sexes 
(p=0.40) (Figure 3B). There was a statistically significant difference when comparing OS 
according to age group (p<0.001) (Figure 3C). Better survival was found for patients under 
75 (median OS: 64 months) than for patients aged ≥75 (median OS: 19 months). 
Differences between periods of diagnosis were not statistically significant (p=0.18) (Figure 
3D). The median OS for patients diagnosed from 1993-1997 was 23 months, compared to 
17 months for patients diagnosed from 1998-2002 and 37 months for those diagnosed from 
2003-2007.  
 
 
 
 
 
 
 
 
 
Discussion 
This study describes the incidence and survival rates for patients diagnosed with CMML in 
the Girona province over the period 1993-2007. This is the first population-based study on 
CMML in Spain. Although some epidemiological studies reported incidence and survival 
data of MDS and myeloproliferative neoplasms (MPN), there are very few population-
based studies related to CMML. Changes in the classification of CMML resulted in data 
collection becoming unreliable and data not being properly recorded in population-based 
cancer registries. Also, the ICD-O-2 did not consider MDS and some MPN malignant, so 
probability some cancer registries did not record them [18,30,31]. 
CMML is widely accepted as being a very rare malignancy, with an incidence lower than 
one case per 100,000 inhabitants/year and an annual average of 4 new cases per year in our 
region. The incidence of CMML in Girona was very low in the population aged <75 and 
increased steadily with advancing age. More than 70% of patients were over 75 (Figure 1). 
This result coincided with the age of patients at time of diagnosis (from 65 to 75 years old) 
and although there was a male predominance, the difference between sexes was not 
statistically significant. The observed incidence rate of CMML was similar to rates reported 
in France and Southeast England. Nevertheless, incidence was higher in Girona than in the 
US (Table 2) [32-34]. The low incidence in the US is probably a consequence of an 
underreported registry of CMML cases. Compared to other cancers, CMML is a 
haematological malignancy diagnosed and managed outside hospitals, and although 
independent laboratories report cases to local registries, the completeness of case reporting 
is not well-known.  
 
The median survival of CMML patients is around 12-24 months and even though it can 
vary from 1 to over 100 months, survival with CMML is extremely poor [2,5-7,11].  In the 
present study, the median OS was 28 months. There were no differences in survival 
between men and women or among periods of diagnosis. With regard to the effect of age 
on survival, we found that survival decreases rapidly with advancing age. 
We also reported a 5-year OS of 20% and a RS of 29%. After comparing our results with 
other international publications we found that there were some variations in RS between 
different countries. RS observed in Girona was higher than in Southeast England and the 
US but lower than in France (Table 3) [32-34]. Differences in survival may be due to 
number of patients, age of population studied, percentage of CMML subtype and 
consequently percentage of transformations into acute myeloid leukemia (AML) and 
treatment used in each case. According to the literature, patients with CMML-1 (less than 
5% of blasts in PB and less than 10% of blasts in BM) survive between 18 and 20 months, 
while patients with CMML-2 (peripheral blasts 5-19% and marrow blasts 10-19%) have a 
slightly lower survival, from 12 to 14 months, as a consequence of the probability of 
developing AML from 1 to 125 months after diagnosis [2,7,11,35-37]. This transformation 
occurs in approximately 18% (15-30%) of cases and survival of these patients decreases up 
to 14 months or less. In this context, AML is called secondary AML (sAML) and has a 
poorer prognosis than CMML [6,7,36].  
 
Currently, no standardized approach to treatment has been proven to be effective or to 
modify the pathogenesis of all CMML patients. Allogenic hematopoietic stem cell 
transplantation remains the only known curative method, but is a possible option in only a 
minority of patients aged 65-75. Most people who suffer CMML are treated with palliative 
drugs and supportive cares such as hydroxyurea, oral etoposide, low-dose citarabine and 
oral topotecan [2,7,35,37]. Although clinical trials have been carried out, the results are still 
not as satisfactory as expected for all patients and more research is needed. An example of 
new treatments recently approved by the Food and Drug Administration (FDA) are 
hypomethylating agents like azacitidine and decitabine, which have demonstrated anti-
MDS activity. These are now being administered for CMML and MDS treatment although 
results are not well known [38-40].    
 
Some limitations of this study must be considered. Firstly, CMML is a disorder which is 
difficult to classify and some cases were probably registered as MDS. Secondly, we must 
take into account that diagnosis methods change and are now more sensitive and precise 
than some years ago. Thirdly, we must also bear in mind the heterogeneity of the data used, 
as they are provided by different hospitals and pathology laboratories. Finally, the GCR 
does not collect clinical data regarding the percentage of blasts to classify CMML into 
prognostic subtypes (CMML-1 or CMML-2).  
 
Conclusions 
This is the first population-based study to analyze the incidence and survival rates of 
CMML in Spain. Taking into account that CMML is a very uncommon blood cancer that 
affects elderly people, these data are useful in determining the population incidence and 
especially the associated disease survival rate. Survival is low among people who suffer 
from CMML and due to the fact that current treatments are not effective, more research is 
required to improve this situation.  
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Figure Legend 
 
Figure 1. Age-specific incidence rate of chronic myelomonocytic leukemia by age groups 
in Girona (Spain), 1993-2007.  
 
Figure 2. Relative and observed cumulative survival of patients with chronic 
myelomonocytic leukemia in Girona (Spain) 1993-2007, by 5-year time periods.  
 
Figure 3A-D. Cumulative survival curves of patients diagnosed with chronic 
myelomonocytic leukemia in Girona (Spain) for 1993-2007. A) Global survival curve with 
95% confidence interval. B) By sex. C) By age groups (<75 years and ≥75years). D) By 
time period (1993-1997, 1998-2002 and 2003-2007) 
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Table Legends 
 
Table 1. Descriptive results and incidence rate for cases of chronic myelomonocytic 
leukemia diagnosed in Girona during the period 1993-2007. 
 
Table2. Age standardized incidence rate reported in some epidemiological studies of 
chronic myelomonocytic leukemia: Girona (Spain), South East England, Côte d’Or 
(France) and the United States. Incidence rates are adjusted by World standard population, 
European standard population and US standard population.  
 
Table 3. Median observed survival in months and relative survival at 1,3,5 years in percent 
(95 % confidence interval) of chronic myelomonocytic leukemia in some epidemiological 
studies: Girona (Spain), South East England, Côte d’Or (France) and United States. 
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Table 1 
 
 Men Women Total 
N 36 25 61 
Mean age (SD) 79.03 (7.31) 78.64 (9.13) 78.87 (8.03) 
Median age 79 80 79 
<65 years  (%) 2.78 4 3.28 
65 -75 years (%) 19.44 28 22.96 
≥ 75 years (%) 77.78 68 73.77 
CR 0.85 0.59 0.72 
 
N (number of cases), SD (standard deviation), CR (crude rate per 100,000 inhabitants/year). 
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Age standardized incidence 
rate/100,000 inhabitants/year 
(95% confidence interval) 
adjusted by: 
  
 
Results obtained in 
this study. Girona 
1993-2007 
(n=61) 
 
Karen et al. 
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(n=99) 
 
Maynadiè et al. 
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1980-2004
34
 
(n=146) 
 
Phekoo et al. 
United States 
2001-2004
32
 
(n=2601) 
World standard population 
Males 
Females 
All 
Sex ratio 
  
 
0.34 (0.23-0.45) 
0.19 (0.11-0.27) 
0.25 (0.18-0.32) 
1.79 
 
0.41 
0.19 
0.28 
2.16 
  
 
 
 
 
 
European standard population 
Males 
Females 
All 
Sex ratio 
 
 
0.61 (0.41-0.81) 
0.32 (0.18-0.45) 
0.43 (0.32-0.54) 
1.90 
 
0.67 
0.32 
0.46 
2.09 
 
0.80 
0.30 
0.50 
3.3 
 
 
 
 
 
 
US standard population 
Males 
Females 
All 
Sex ratio 
 
0.84 (0.56-1.11) 
0.40 (0.24-0.55) 
0.57 (0.43-0.71) 
2.10 
   
 
 
0.37 
 
Table
Table 3 
 
   
OS 
 
 
RS 
Survival Median 
(months) 
1 year 3 years 5 years 10 years 
Results obtained in this study, Girona 1993-2007 (n=61) 
Total  
Male 
Female 
 
28 
20 
30 
 
78 (67-91) 
73 (58-91) 
85 (70-100) 
 
49 (36-67) 
45 (27-67) 
58 (39-87) 
 
29 (17-49) 
29 (15-57) 
28 (12-65) 
 
Phekoo  et al, South East England 1999-2001
33
 (n=99) 
 
Total  
Male 
Female 
<65 years 
≥ 65 years 
14 
14 
13 
14 
14 
52 (42-62) 
55 (45-65) 
54 (40-66) 
60 (12-88) 
52 (42-62) 
29 (20-39) 
32 (23-42) 
25 (14-37) 
20 (8-58) 
31 (21-41) 
  
Maynadiè et al, Côte d'Or (France) 1980-2004
34
 (n=146) 
 
Total  26.6   34(24-44) 19 (9-32) 
Rollinson et al, United States 2001-2004
32
 (n=2601) 
 
Total  
Male 
Female     
21 (16-26) 
18 (12-23) 
27 (18-35)     
 
n (number of cases), OS (observed survival), RS (relative survival). 
 
Table
